Conditions: Ovarian Neoplasms
Keywords: Peritoneal Neoplasma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 246
Healthy volunteers: no

Brief summary:
Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.

Detailed description:

Arms:
arm 1: Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid) arm 2: Participants received 2 matching placebo tablets per oral twice daily

Interventions: intervention 1: Sorafenib (Nexavar, BAY43-9006) intervention 2: Placebo
Intervention descriptions: intervention 1: Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration. intervention 2: Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.

Protocol document: